Structure Therapeutics Inc. (GPCR) Key Metrics
GPCR valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.50B
- Enterprise value
- $1.23B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.9 10-yr median 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −1.37
GPCR key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGPCR valuation Price multiples at each fiscal year-end price.
GPCR returns How much profit the business earns on the capital it uses.
GPCR per-share figures Results divided by the shares outstanding at year-end.
GPCR financial health Debt, liquidity and how easily interest is covered.
GPCR efficiency & capital use Working capital cycle and where the cash goes.
GPCR valuation history
GPCR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GPCR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GPCR cash returned to shareholders
GPCR price vs earnings per share
GPCR key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $4.12B | $1.43B | $1.50B | — | — | — |
| Enterprise value | $2.68B | $548.0M | $1.04B | — | — | — |
| Price / book | 2.7 | 1.7 | 3.3 | — | — | — |
| Earnings yield | −3.4% | −8.6% | −6.0% | — | — | — |
| Free cash flow yield | −5.5% | −8.3% | −5.5% | — | — | — |
| Share price at fiscal year-end | $69.55 | $27.12 | $40.76 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.39 | −$2.33 | −$2.44 | −$1.40 | −$1.09 | −$0.00 |
| Operating cash flow per share | −$3.75 | −$2.22 | −$2.16 | −$1.26 | −$0.88 | −$0.39 |
| Free cash flow per share | −$3.81 | −$2.24 | −$2.22 | −$1.26 | −$0.91 | −$0.39 |
| Cash per share | $24.43 | $16.78 | $12.72 | $2.48 | $2.93 | $1.02 |
| Book value per share | $25.62 | $16.43 | $12.33 | −$3.15 | −$1.77 | −$0.61 |
| Tangible book value per share | $25.62 | $16.43 | $12.33 | −$3.15 | −$1.77 | −$0.61 |
| Capex per share | $0.06 | $0.02 | $0.06 | $0.00 | $0.03 | $0.00 |
| Debt per share | $0.11 | $0.07 | $0.15 | $0.01 | $0.02 | $0.01 |
| Shares outstanding | 59.2M | 52.6M | 36.7M | 36.6M | 36.6M | 36.6M |
| Change in shares outstanding | +12.5% | +43.3% | +0.4% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −11.9% | −18.6% | −53.1% | — | — | — |
| Return on invested capital (ROIC) | −734.6% | — | — | — | — | — |
| Return on assets (ROA) | −11.4% | −17.7% | −30.9% | −49.1% | −53.4% | −0.0% |
| Return on tangible assets | −8.9% | −13.6% | −18.6% | −52.5% | −36.0% | −0.0% |
| Financial health | ||||||
| Total debt | $6.5M | $3.9M | $5.5M | $260,000 | $621,000 | $280,000 |
| Cash & short-term investments | $1.45B | $883.5M | $467.3M | $90.8M | $107.3M | $37.4M |
| Net debt | −$1.44B | −$879.7M | −$461.9M | −$90.6M | −$106.7M | −$37.2M |
| Debt / equity | 0.00 | 0.00 | 0.01 | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 |
| Current ratio | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Quick ratio | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Interest coverage | — | — | -7.7 | -34.3 | -308.6 | — |
| Working capital | $1.51B | $855.2M | $448.9M | $80.1M | $100.6M | $35.4M |
| Invested capital | $76.7M | −$14.8M | −$8.9M | −$205.7M | −$171.4M | −$59.6M |
| Tangible asset value | $1.52B | $864.8M | $453.0M | −$115.1M | −$64.7M | −$22.5M |
| Net current asset value | $1.50B | $852.7M | $444.6M | −$119.9M | −$66.6M | −$22.8M |
| Graham net-net per share | $23.29 | $16.05 | $11.93 | −$3.34 | −$1.87 | −$0.65 |
| Capital allocation | ||||||
| Share buybacks (net) | — | — | — | $6,000 | — | — |
| Capex / depreciation | 2.71 | 1.30 | 7.35 | 0.56 | 16.75 | 0.83 |
| Efficiency | ||||||
| Days payables outstanding | 1,024.4 | 896.7 | 2,067.1 | 2,779.7 | 3,433.4 | 27,820.5 |
| Payables turnover | 0.36 | 0.41 | 0.18 | 0.13 | 0.11 | 0.01 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $10.9M | $6.4M | $5.4M | $4.7M | $2.5M | $1.5M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GPCR's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GPCR valuation and financial ratios
Structure Therapeutics earned a return on equity of −11.9% and a return on invested capital of −734.6% in fiscal 2025. It ended the year with $6.5 million of debt and $1.4 billion in cash and short-term investments, a net cash position of $1.4 billion. The share count rose 61.8% from 36.6M to 59.2M over 5 years.
See the GPCR income statement, the GPCR chart for price history, or the GPCR stock overview for the latest quote and news.
GPCR key metrics FAQ
What is Structure Therapeutics's return on equity?
Structure Therapeutics's return on equity (ROE) was −11.9% in fiscal 2025: net income of -$141.2 million on average shareholders' equity of $1.2 billion.
What is Structure Therapeutics's ROIC?
Structure Therapeutics's return on invested capital was −734.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Structure Therapeutics have?
Structure Therapeutics had total debt of $6.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Structure Therapeutics's free cash flow yield?
Structure Therapeutics generated -$225.8 million of free cash flow in fiscal 2025, a free cash flow yield of −5.5% on its market value at year-end ($4.1 billion).
What is Structure Therapeutics's current ratio?
Structure Therapeutics's current ratio was 24.81 at the end of fiscal 2025: current assets were 24.81 times current liabilities.